Phosphatidylinositol 3-kinases (PI3Ks) are important regulators of signaling pathways. To determine whether PI3Ks are genetically altered in human cancers, we recently analyzed the sequences of the PI3K gene family and discovered that one member, the PIK3CA gene encoding the p110α catalytic subunit, was frequently mutated in cancers of the colon, breast, brain and lung. The majority of mutations clustered near two positions within the PI3K helical or catalytic domains and at least one hotspot mutation appeared to increase kinase activity. PIK3CA represents one of the most highly mutated oncogenes identified in human cancers and may be a useful diagnostic and therapeutic target.
PI3K SIGNALING AND ITS DEREGULATION IN CANCER
PI3Ks are lipid kinases that are important in controlling signaling pathways involved in cell proliferation, cell death, motility and cell invasion. [1] [2] [3] Class I A PI3Ks normally exist as heterodimers comprised of a p110 catalytic subunit and a p85 regulatory subunit and can be activated by recruitment to the cell membrane via receptor tyrosine kinases or RAS. Active PI3Ks phosphorylate phosphatidylinositol (4, 5) bisphosphate (PIP 2 ) at the 3-position on the inositol ring, converting it to phosphatidylinositol (3, 4, 5) triphosphate (PIP 3 ). PIP 3 acts as an anchor for the AKT serine/threonine kinase (also known as protein kinase B, PKB) and for 3-phosphoinositide-dependent protein kinase-1 (PDK1), both of which bind PIP 3 via their pleckstrin homology (PH) domains. Once at the membrane, PDK1 phosphorylates and activates AKT which then regulates a range of target proteins involved in a variety of intracellular processes.
Deregulation of the PI3K pathway has been directly implicated in several human cancers. The best known genetic alteration of this pathway is the loss of the tumor suppressor PTEN which dephosphorylates the lipid product of PI3Ks. 4, 5 Genetic inactivation of PTEN results in high levels of PIP3 and constitutive activation of the PI3K pathway. Additionally, amplification of genomic regions containing AKT and PIK3CA has been reported in some human tumors, 1, 6, 7 but the genes that are targets of such amplification are not easily defined. Interestingly, increased levels of PI3K activity has been reported in a substantial fraction of colorectal and other tumors, 8, 9 suggesting that additional alterations may be present in this pathway.
The development of automated sequencing technology and the completion of the human genome project has allowed high throughput mutational analysis of cancer genomes. We have used this approach to evaluate gene families involved in signal transduction and chromosomal instability for genetic alterations. [10] [11] [12] We recently used these tools to determine if PI3Ks were genetically altered in tumorigenesis by sequencing all of the PI3K genes in human cancers and corresponding normal tissues. 13 We will briefly review here the results obtained from this study as well as the subsequent mutational analyses of PIK3CA in other tumor types, 14, 15 and discuss their therapeutic and diagnostic implications.
DETECTION OF PIK3CA MUTATIONS IN COLON CANCER
The PI3K gene superfamily is composed of four major classes. Class I, II and III genes encode proteins which possess lipid kinase activity whereas class IV encode serine/threonine kinases that are similar to PI3Ks. 16 Using a bioinformatics analysis employing Hidden Markov Models representing catalytic domains of members of the PI3K family, we identified 8 class I-III PI3Ks, and 8 class IV PI3Ks in the human genome. As an initial screen to evaluate whether these PI3Ks were genetically altered in human cancer, we analyzed the coding exons of the kinase domain of all 16 members of this gene family in a panel of 35 colorectal cancers. 13 A total of 117 exons were extracted from genomic databases, and these sequences were PCR amplified and directly sequenced from tumor DNA. Whenever a sequence alteration was identified, we attempted to determine whether it was a somatically acquired mutation (i.e., tumor-specific) by examining the sequence of the gene in genomic DNA from normal tissue of the relevant patient.
From this analysis, PIK3CA was the only gene that was observed to have somatic mutations. To further evaluate the pattern of somatic mutations in PIK3CA, we sequenced all coding exons of this gene in 199 additional colorectal cancers and identified mutations in 74 tumors (32%). All but three of the alterations were heterozygous and no truncating or nonsense alterations were observed.
To determine at what stage of colorectal cancer PIK3CA mutations occur, 76 premalignant colorectal tumors were also examined. This analysis identified only two mutations, both in advanced adenomas, suggesting that PIK3CA mutations arise late in tumorigenesis, just before or concurrent with invasion.
Over 80% of the mutations observed in PIK3CA clustered in small "hotspot" regions in the helical (exon 9), kinase (exon 20), and p85 binding (exon 1 and 2) domains (Fig. 1) . The clustering of mutations in PIK3CA is reminiscent of alterations in other oncogenes such as KRAS, BRAF, CTNNB1, and certain tyrosine kinases. 10, [17] [18] [19] In cancers, many of these genes possess hotspot alterations in catalytic regions which result in constitutive activation of the encoded mutant protein. Interestingly, the majority of tumors with PIK3CA mutations also contained mutations in KRAS or BRAF, suggesting that PIK3CA is likely to operate through cellular pathways distinct from those associated with these genes.
PIK3CA IS MUTATED IN A BROAD RANGE OF TUMOR TYPES
Examination of PIK3CA in seven additional tumor types identified mutations in four of 15 (27%) glioblastomas, three of 12 (25%) gastric cancers, one of 12 (8%) breast, and one of 24 (4%) lung cancers, while no mutations were observed in 11 pancreatic cancers or 12 medulloblastomas. 13 Two subsequent studies have expanded the mutational analysis of PIK3CA in breast cancer 14 and various brain tumors. 15 The Bachman et al. study demonstrated that thirteen out of fifty breast cancers (25%) contained somatic mutations in PIK3CA, with the majority of the mutations located in the kinase domain (exon 20). Importantly, this study places the PIK3CA gene as one of the most highly mutated genes in human breast cancer.
A comprehensive examination of the helical and catalytic domains of PIK3CA in brain tumors identified 13 mutations in 285 tumors (5%). 15 These alterations were observed in anaplastic oligodendrogliomas, anaplastic astrocytomas, glioblastoma multiforme and medulloblastomas. No mutations were found in low-grade astrocytomas and only one mutation was observed among 31 anaplastic astrocytomas. This suggests that PIK3CA alterations occur at later stages of glioma progression, in a manner analogous to that of PIK3CA mutations occurring at relatively late stages of colorectal cancer progression. The frequency of mutations in glioblastomas found by this study (5%) was lower than the one found previously by Samuels et al. (25%). As the majority of glioblastoma mutations reported by Samuels et al. were in positions outside the hotspot regions, this difference may be due to the limited number of exons examined in the Broderick et al. study (only exons 9 and 20). It will be interesting to determine if mutations in other regions of the gene are a consistent feature of glioblastomas as this would suggest that the spectrum of PIK3CA mutations may differ among cancer types.
WHAT ARE THE FUNCTIONAL EFFECTS OF THE HOTSPOT MUTATIONS?
The nature and positions of the mutations within PIK3CA imply that they are likely to be oncogenic. Nearly all of the alterations found to date have been heterozygous missense changes and many of these affect highly conserved residues. The presence of hotspot clusters of alterations suggested that these changes may be kinase activating, similar to oncogenic mutations in protein kinases. To determine the biologic consequences of a hotspot alteration on p110α function, wild-type p110α or a hostpot mutant (H1047R) were transiently transfected into NIH3T3 cells and their in vitro lipid kinase activity was evaluated. 13 Expression of mutant H1047R p110α resulted in significantly more lipid kinase activity than the wild-type protein.
These data demonstrated that mutation in the catalytic domain of PIK3CA results in kinase activation. How this occurs mechanistically is unclear, but may be similar to oncogenic activation of protein kinases by mutation in their catalytic domains. 20 This is consistent with the observation that the 1047 hotspot region in p110α is adjacent to a segment that is analogous to the frequently mutated activation loop in protein kinases. 20 frequent hotspot cluster occurs in exon 9 which is within the helical domain of p110α. Crystal structure analyses of the related protein p110γ suggest that the helical domain serves as a spine on which the other domains are fastened, and may be a site of interaction with other regions, regulatory subunits, or other proteins. 21, 22 The third hotspot cluster in exons 1 and 2 falls within the p85 binding domain. Studies have shown that in order for p110α to be active it has to be brought to the cell membrane by p85. 1, 23 However, mutations in p85 lead to p110α activation, presumably by removal of p85 inhibition on kinase function. 24 It is tempting to speculate that the mutations in this domain abrogate the p85 inhibitory function on p110α resulting in kinase activation. Clearly, many questions remain to be answered regarding the biochemical and cellular effects of the various p110α mutations. For example, what effect do different mutations have on p110α structure and its interaction with p85? Do all mutations result in p110α kinase activation? Are mutations in different domains equally tumorigenic? Additional biochemical and structural work will be needed to fully explore the effect of these alterations on p110α function.
FURTHER GENETIC ANALYSES
The significance of the PIK3CA pathway in cancer could be further elucidated by additional mutational analyses of other genes involved in PI3K signaling. Work is currently underway to evaluate whether mutations of PIK3CA occur in tumors with mutations in PTEN, or whether such alterations are mutually exclusive, as is the case with KRAS and BRAF. 18, 25 This would provide genetic evidence that these genes act in an equivalent fashion during tumorigenesis. Mutational analyses of other proposed members of PI3K pathway might identify additional genes which are mutationally altered in neoplasia. The outcome of such studies may be to increase the already sizeable number of individuals who have mutations in the PI3K pathway and to provide an even stronger rationale for development of new therapeutic and diagnostic approaches for these individuals.
DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS
One of the most effective clinical interventions for many cancers is the early detection and surgical removal of neoplastic lesions. In an effort to improve early detection of colorectal cancers, several novel noninvasive diagnostic assays have recently been developed. [26] [27] [28] Such tests work by detecting tumor-derived genetic alterations in patient stool samples. Although highly specific, these analyses have a limited sensitivity (~60%), in part due to the difficulty of detecting mutations present at widely varying positions in the APC tumor suppressor gene. 27 In contrast, nearly 80% of alterations in PIK3CA are localized to two small clusters within the gene, each less than 120 bp in size. Clinical analysis of these mutations in PIK3CA may therefore be a cost-effective way to increase the sensitivity of existing diagnostic tests by as much as ~20%. One could envision development of similar diagnostic tests for PIK3CA mutations from various bodily fluids in order to detect other types of cancer. 26 Oncogenes such as PIK3CA which encode mutant enzymes provide opportunities for targeted inactivation by therapeutic compounds. The success of small-molecule inhibitors such as Gleevec against BCR-ABL 29 and Iressa against EGFR 30, 31 suggests that rationally developed drugs can be successfully used to inhibit certain kinases. For PIK3CA, an encouraging aspect is the availability of chemical compounds such as wortmannin and LY294002 which inhibit PI3Ks and have been shown to reduce tumor progression. 1, 32 Such compounds suggest that PIK3CA can be successfully targeted and may be amenable to inhibition by more specific compounds. Development of therapies that affect only mutant forms of PIK3CA provide an additional way to increase specificity and limit toxicity of such inhibitors. Ultimately, one could imagine individualized therapy based on presence of mutant PIK3CA in specific tumors. This approach would have broad therapeutic use given the high fraction of various tumor types that are mutated in the PI3K pathway.
